Medical professional liability claims and esophageal cancer screening

September 30, 2014, The JAMA Network Journals

An analysis of liability claims related to esophageal cancer screening finds that the risks of claims arising from acts of commission (complications from screening procedure) as well as acts of omission (failure to screen) are similarly low, according to a study in the October 1 issue of JAMA.

Endoscopic screening for esophageal cancer has been recommended for patients with chronic symptoms of , but only if they have additional risk factors. Surveys of gastroenterologists indicate that concern about litigation for missing a cancer may drive endoscopy use in patients at low risk for esophageal cancer. However, the perception of medical professional liability may not accurately reflect the true incidence of liability claims, according to background information in the article. Although the rate of serious adverse events arising from esophagogastroduodenoscopies (esophageal cancer screening procedure) is small, 6.9 million were performed in the United States in 2009.

Megan A. Adams, M.D., J.D., of the University of Michigan, Ann Arbor, and colleagues, using data from a medical professional liability claims database, identified all claims relating to a diagnostic esophagogastroduodenoscopy (1985-2012), and then restricted to claims alleging inadequate indication for esophagogastroduodenoscopy. They also identified claims related to esophageal cancer restricted to those alleging delay in diagnosis, and excluded claims in which the presenting condition was an alarm symptom or sign (defined as weight loss, dysphagia [difficulty swallowing], or ), and those in which the presenting condition was a cancer of the esophagus or cardia (top portion of the stomach) or an abnormal radiographic finding.

A total of 761 claims filed from 1985-2012 against physicians were related to esophagogastroduodenoscopy. The leading types of misadventure (error) alleged were improper performance (n = 267), errors in diagnosis (n = 186), and no medical misadventure (i.e., claims that did not involve a purely medical error, such as abandonment, breach of confidentiality, or consent issues) (n = 147). Seventeen claims (2.2 percent) alleged inadequate indication for esophagogastroduodenoscopy. A total of 268 claims in 1985-2012 involved esophageal malignancies, including 122 in 2002-2012. Of these, 62 (50.8 percent) alleged delay in diagnosis. Nineteen claims reported nonalarm presenting symptoms.

"We found a low incidence of reported medical professional liability claims against physicians for failure to screen for esophageal cancer in patients without alarm features (19 claims in 11 years, 4 paid). In contrast, in 28 years, there were 17 claims for complications from esophagogastroduodenoscopies with questionable indication (8 paid). This suggests that the risks of medical professional liability claims arising from acts of commission as well as acts of omission in endoscopic screening are similarly low," the authors write.

"There may be legitimate reasons to screen for in some patients, but our findings suggest that the risk of a liability claim for failing to screen is not one of them. Physicians need to balance the risk of complications from diagnostic procedures, even if those complications are rare."

Explore further: Uncertainty noted in seemingly stable medical liability climate

More information: DOI: 10.1001/jama.2014.7960

Related Stories

Uncertainty noted in seemingly stable medical liability climate

December 30, 2013
(HealthDay)—Although the medical liability climate seems stable, the impact of health care reform on the market is uncertain, according to an article based on two reports published by the American Medical Association (AMA).

Risk of esophageal cancer decreases with height

September 25, 2014
Taller individuals are less likely to develop esophageal cancer and it's precursor, Barrett's esophagus, according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the ...

Massachusetts primary care malpractice claims related to alleged misdiagnoses

September 30, 2013
Most of the primary care malpractice claims filed in Massachusetts are related to alleged misdiagnoses, according to study in JAMA Internal Medicine by Gordon D. Schiff, M.D., of the Harvard Medical School and Brigham and ...

Missed diagnoses and drug errors make up bulk of primary care malpractice claims

July 18, 2013
Missed diagnoses―particularly of cancer, heart attack, and meningitis―and drug errors make up the bulk of malpractice claims brought against doctors in primary care, finds an analysis of published data in the online journal ...

Statins may lower esophageal cancer risk

June 6, 2013
(HealthDay)—Statins may lower the risk of esophageal cancer, particularly in patients with Barrett's esophagus, according to a review published in the June issue of Clinical Gastroenterology and Hepatology.

Recommended for you

Could the zika virus fight the brain cancer that killed john McCain?

September 18, 2018
(HealthDay)—Preliminary research in mice suggests that the Zika virus might be turned from foe into friend—enlisted to curb deadly glioblastoma brain tumors.

Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort

September 18, 2018
The consumption of foods with higher scores on the British Food Standards Agency nutrient profiling system (FSAm-NPS), reflecting a lower nutritional quality, is associated with an increased risk of developing cancer, according ...

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

Artificial intelligence can determine lung cancer type

September 17, 2018
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.

Researchers develop mechanism for characterizing function of rare tumor cells

September 17, 2018
Scientists have long known that circulating tumor cells, rare cancer cells that are released into the bloodstream, have the potential to provide vital information about a person's specific cancer. But until now, they have ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.